Clinical trials: Prednisolone
Lymphoma
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma.
- Trial name
- NCT00004228
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 176 sites in United States, Australia and 3 more
- Volunteers
- 393 people
- Sponsor
- Children's Oncology Group
Lymphoma
S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, gemcitabine, and methylprednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00109928
- Testing
- cisplatin, etoposide, gemcitabine
- Where
- 77 sites in United States
- Volunteers
- 34 people
- Sponsor
- SWOG Cancer Research Network
Chronic Graft-versus-host Disease
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
- Trial name
- NCT03584516
- Testing
- Itacitinib, Methylprednisolone, Prednisone
- Where
- 133 sites in United States, Austria and 14 more
- Volunteers
- 155 people
- Sponsor
- Incyte Corporation
Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
- Trial name
- NCT00557193
- Testing
- Asparaginase, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 170 sites in United States, Australia and 2 more
- Volunteers
- 218 people
- Sponsor
- Children's Oncology Group
Sudden Deafness
Sudden Deafness Treatment Trial
This trial aims to compare the efficacy of oral prednisone vs. methylprednisolone injected into the middle ear for the treatment of moderate-to-severe, sudden sensorineural hearing loss (inner ear hearing loss affecting one ear…
- Trial name
- SSNHL (NCT00097448)
- Testing
- prednisone, methylprednisolone sodium succinate
- Where
- 14 sites in United States
- Volunteers
- 255 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Myasthenia Gravis
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
The purpose of this trial is to determine if thymectomy combined with prednisone therapy is more beneficial in treating non-thymomatous myasthenia gravis than prednisone therapy alone.
- Trial name
- NCT00294658
- Testing
- thymectomy plus prednisone, prednisone alone
- Where
- 70 sites in United States, Argentina and 16 more
- Volunteers
- 126 people
- Sponsor
- University of Alabama at Birmingham
Hypospadias
Effect of Steroids on Post-Operative Complications Following Proximal Hypospadias Repair
The primary objective of this study is to determine the efficacy of administering a course of postoperative oral steroids in pediatric patients undergoing proximal hypospadias repair as prevention against complications.
- Trial name
- NCT02162810
- Testing
- Prednisolone
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Francis Schneck
Heart Transplant
Tocilizumab in Cardiac Transplantation
The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant.
- Trial name
- NCT03644667
- Testing
- tocilizumab, Standard of Care Triple IS
- Where
- 20 sites in United States
- Volunteers
- 385 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sudden Sensorineural Hearing Loss
Oral Statins and Protection From Hearing Loss
A small clinical trial for idiopathic sudden sensorineural hearing loss (ISSNHL). Will the addition of an oral statin to the standard treatment (oral methylprednesolone and the salvage therapy of intratympanic dexamethasone)…
- Trial name
- NCT04826237
- Testing
- Statin, methylprednisolone, dexamethasone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Rheumatoid Arthritis
Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis
This is a phase 2a study to be run in 2-3 countries in European Union involving 5-6 sites. It will enroll approximately 80 patients to ensure 40 randomized with active rheumatoid arthritis.
- Trial name
- NCT03368235
- Testing
- AZD9567, Prednisolone
- Where
- 5 sites in Netherlands, Sweden
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia
- Trial name
- NCT00792948
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine
- Where
- 157 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
Rheumatoid Arthritis
A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)
This is a study of the overall safety, tolerability, and pharmacokinetics (PK) of MK-8808 versus rituximab (MabThera® and Rituxan®) in participants with moderate to severe RA with an inadequate response or intolerance to…
- Trial name
- NCT01390441
- Testing
- MK-8808, MabThera® (rituximab), Methotrexate
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes
The study is intended to assess the effect on glycaemic control of AZD9567, as measured by the glucose AUC(0-4) versus baseline following a standardised mixed meal tolerance test (MMTT), compared to prednisolone in adults with…
- Trial name
- NCT04556760
- Testing
- AZD9567, Prednisolone
- Where
- 3 sites in Germany
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Pemphigus
Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris
This study is designed as a multi-country, multicenter, open label extension to Phase III trial OPV116910. The primary objective is to provide continued treatment with ofatumumab subcutaneous (SC) for eligible subjects who…
- Trial name
- NCT02613910
- Testing
- Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent)
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Prostatic Neoplasms, Neoplasm Metastasis
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Primary objective was to demonstrate overall survival improvement with aflibercept compared to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent prostate cancer (MAIPC).
- Trial name
- VENICE (NCT00519285)
- Testing
- Aflibercept, Docetaxel, Prednisone or Prednisolone
- Where
- 31 sites in United States, Argentina and 29 more
- Volunteers
- 1,224 people
- Sponsor
- Sanofi